Research highlights IBS drugs offering best risk-benefit odds - ProHealth
|
Based on analysis of more than two dozen major clinical trials, two well-studied drug therapies – rifaximin and lubiprostone – offer irritable bowel syndrome (IBS) patients the best odds of benefit without harmful side effects, according to research led by the GI Motility Lab at Cedars-Sinai Medical Center in New York. ... Besides Cedars-Sinai, other centers participating in the research included the School of Medicine at Texas Tech University’s Health Sciences Center; the UCLA Department of Medicine; Beth Israel Deaconess Medical Center; and Harvard Medical School. Funding for the study was provided by the Beatrice and Samuel A. Seaver Foundation. Read the full story >> |
Related Stories
Celebrating Veterans: TTUHSC’s General Martin Clay’s Legacy of Service and Leadership
From his initial enlistment in the Army National Guard 36 years ago to his leadership in military and civilian health care management roles, Major General Martin Clay’s career has been shaped by adaptability, mission focus and service to others.
Texas Tech University Health Sciences Center School of Nursing Named Best Accelerated Bachelor of Science in Nursing Program in Texas
The TTUHSC School of Nursing Accelerated Bachelor of Science in Nursing (BSN) program has been ranked the No. 1 accelerated nursing program in Texas by RegisteredNursing.org.
TTUHSC Names New Regional Dean for the School of Nursing
Louise Rice, DNP, RN, has been named regional dean of the TTUHSC School of Nursing on the Amarillo campus.
Recent Stories
Celebrating Veterans: TTUHSC’s General Martin Clay’s Legacy of Service and Leadership
From his initial enlistment in the Army National Guard 36 years ago to his leadership in military and civilian health care management roles, Major General Martin Clay’s career has been shaped by adaptability, mission focus and service to others.
Project Team Analyzing Survey Results to Increase TTUHSC Grant Funding Capacity
A project team conducted a capacity-building study during the last year aimed at increasing TTUHSC's overall NIH funding. The team is led by Lance McMahon, Ph.D.
NIH-Funded Exploratory Study to Seek Possible Targets for Treating Alcohol Use Disorder
In an effort to uncover therapeutic targets of AUD, the National Institute on Alcohol Abuse and Alcoholism at the NIH awarded a two-year, $407,468 grant to Dawei Li, Ph.D., from the TTUHSC School of Medicine and GSBS.